Ambagon Therapeutics
@ambagontx
Followers
137
Following
0
Media
104
Statuses
124
Expanding the druggable proteome to drug intrinsically disordered proteins.
Joined January 2022
This month we had the pleasure of welcoming Vicky Lin as Sr. Principal Scientist to our Cell Biology team in San Carlos, CA. For more on our team:
0
0
1
Our scientific co-founders Luc Brunsveld, @MichelleArkin, @COttmann1433 and colleagues recently described a proteomics approach to identify proteins stabilized to the 14-3-3 adaptor proteins in cancer cells, expanding the 14-3-3 interactome. Check it out:
0
0
0
At Ambagon, our scientists have deep expertise in the structure and interactions of the 14-3-3 regulatory hub proteins and have leveraged this knowledge to develop a platform to drug intrinsically disordered proteins. View our platform on our website:
0
0
0
Our team is developing a new class of medicines that can modulate some of the most challenging drug targets identified across the proteome. Learn more about our approach:
0
1
1
Our co-founders, Luc Brunsveld, @MichelleArkin & @COttmann1433 recently published a paper on a molecular lock approach that enables the stabilization of protein complexes. These advances support the discovery and modeling of molecular glues. Read it here:
pubs.acs.org
Molecules that stabilize protein–protein interactions (PPIs) are invaluable as tool compounds for biophysics and (structural) biology, and as starting points for molecular glue drug discovery....
0
1
1
Ambagon observes #Juneteenth. We celebrate the end of slavery in America and are committed to creating a more equitable future for all, starting with an inclusive work environment and a diverse team. Learn more about Ambagon’s team here:
0
0
0
June is #NationalCancerSurvivorsMonth. This month, and every month, we are committed to expanding the boundaries of medicine and developing life changing therapies for people with cancer.
0
0
0
Join our team! We’re hiring a Senior Research Associate/Associate Scientist, Proteomics for an integral role in designing and implementing innovative proteomics methods to support our drug discovery efforts. Learn more and apply today: #biotechjobs
0
0
0
June is #PrideMonth! We are committed to a culture of #diversity and #respect among team members and the community. These values unite us and keep us focused on our goal of helping patients live longer, healthier lives. Learn more:
0
0
0
Meet Nancy Deng, Ph.D., Senior Director, Computational Chemistry! Her experience in molecular dynamics and protein-peptide modelling adds tremendous value to our protein stabilization efforts. Visit our website to learn about our full team:
0
0
0
Ambagon is guided by global leaders in 14-3-3 protein structure and biology, with more than 100 years of drug development experience. Our leadership team is passionate about helping patients live longer, healthier lives. Learn about our leadership team:
0
0
0
To us, Trust means having confidence in one another, communicating constructively and being a reliable source for teammates who may need a helping hand. Trust is one of our six core values that guide our work each day. View our full list of values here:
0
0
0
We study the structural biology of 14-3-3 proteins because of their role in numerous protein-protein interactions (PPIs). We aim to use the ability to modulate these PPIs to address unmet needs in cancer, neurodegenerative and other diseases. Learn more:
1
0
0
Our structural biology team uses complementary approaches, such as crystallography and NMR to enable structure-based design of our 14-3-3 molecular glues and accelerate our drug development. Meet the team:
0
1
1
May is #NationalCancerResearchMonth. Our oncology pipeline focuses on targets involved in oncogenic signaling and gene expression, cell cycle dysregulation, and other cancer-driving processes. #cancerresearch #NCRM23
0
1
1
Ambagon’s Loes Stevers, Ph.D., Sr. Scientist, will present at Fe+male Tech Heroes on May 16. The presentation will highlight our mission to target currently undruggable proteins by developing a new class of medicines through 14-3-3 molecular glues.
0
0
1
We are recruiting a cell biologist to join our team in the SF Bay Area at the SRA level. This role offers an opportunity to apply novel cell biology approaches to develop molecular glue therapeutics for oncology and other diseases. Learn about the role:
0
1
1
One of our scientific co-founders, Luc Brunsveld, was awarded a significant grant by @ERC_Research to allow his laboratory at @TUeindhoven to research protein-protein interactions (PPIs) and molecular glues
tue.nl
Research led by Luc Brunsveld on new technological concepts for drug development is awarded a prestigious ERC Advanced Grant worth 2.5 million euros.
0
0
0
We’re excited to welcome Kateryna Le Meur, Lab Manager, to Ambagon! Kateryna will manage the labs of both our San Carlos and South San Francisco sites. Welcome!
0
0
0
With an extended repertoire of biochemical and biophysical assays this team is at the forefront of evaluating selectivity and potency of our novel small molecules. Meet our biochemistry team:
0
0
0